Pipeline
MacuCLEAR's Co-founder, Chief Scientific Officer, and inventor, has developed a pipeline of compounds for treating various diseases of the eye. Its lead compound MC-1101, is a 505 b 2, repurposed compound, formerly used as an anti-hypertensive drug. Its vasodilation, anti-inflammatory, and antioxidation combined properties is proving effective in modulating choroidal blood flow in human clinical trials. MacuCLEAR's pipleline includes a total of at least 12 separate compounds of various types that are intended to be second generation dry AMD compounds, and in some cases treat other retinal diseases such as diabetic retinapothy and diabetic macula edema. Ten of these proprietary compounds are new chemical entities. MacuCLEAR's second drug MC-4001 is an interluekin-1inhibitor intended to treat diabetic diseases of the eye.